HRA003396
Title:
Proteogenomics landscape of Acute Myeloid Leukemia
Release date:
2024-10-02
Description:
Acute myeloid leukemia (AML) is a malignant hematological cancer with the worst prognosis of all leukemia categories. Here, we reported a comprehensive proteogenomic analysis of 101 Chinese AML patients, including proteomic, phosphoproteomic analysis. We explored the impact of genomic alterations on proteomic and phosphoproteomic characterizations, and also uncovered the protein and phosphosite panel as prognostic indicators.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
Acute myeloid leukemia
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
Lijia Group Bioinformatics Core
Contact person:
Luo Guanghao
Email:
guangho2743@foxmail.com
Description:
Professor Li and his group have established multi-targets screening, multi-function confirmation, and multi-index efficacy evaluation system for diabetes and cancer drug discovery, built up enzyme family based multi-target integrated high throughput screening platform, in line with international standards. Up to now, his team has completed over million data points in drug screening and discovered hundreds of bioactive compounds. As one of the major inventors, Professor Li led four drug candidates targeting metabolic diseases and two drug candidates targeting tumor with independent intellectual property rights, of which pre-clinical studies are under way. Among this, one of the drug candidates has been successfully transferred to a local pharmaceutical company and move forward cooperatively.
Individuals & samples
Submitter:   Li Jia / jli@simm.ac.cn
Organization:   Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Submission date:   2022-11-03
Requests:   -